ZT009

ZT009 is a novel, unimolecular, long-acting dual agonist of the glucagon-like peptide-1 (GLP-1) and amylin receptors, currently in preclinical development for the treatment of obesity. Developed as an engineered peptide conjugate, ZT009 consists of GLP-1 and amylin analogs joined by a peptide linker and acylated with a fatty acid to extend its duration of action. In preclinical studies, ZT009 demonstrated a balanced pharmacological profile with enhanced amylin receptor-3 (AMY3R) activity and moderated GLP-1 activity compared to amycretin, aiming to maximize metabolic benefits while minimizing gastrointestinal side effects. It has shown superior weight loss efficacy and a significantly prolonged half-life across multiple animal species, including rats, minipigs, and monkeys, suggesting potential for infrequent dosing and improved tolerability in clinical settings.